Owkin, the agentic AI company focused on drug discovery and development, has announced an agreement with AstraZeneca to develop biopharma agents as part of a three-year licensing deal for K Pro, Owkin’s AI Scientist platform for biopharma decision-making.
Under the agreement, Owkin will lead end-to-end development of AI agents for K Pro, integrated into AstraZeneca’s IT infrastructure and decision workflows. The agents are intended to help AstraZeneca’s decision-making teams access timely, data-rich insights for competitive intelligence questions, reducing reliance on manual analysis while operating within established governance, security, and enterprise standards.
K Pro brings multimodal data and specialized biological-agentic AI to every step of the pharmaceutical value chain. Among the capabilities to be developed are tools to quickly analyze and forecast the competitive landscape for specific pharmaceutical targets, assets, and clinical trials.
The new agreement builds on a previous collaboration between Owkin and AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Results from that project, published at ESMO, showed that the BRCAura RUO solution could rule out approximately 40% of patients who are unlikely to carry gBRCA mutations, with a sensitivity of 93%. That work now continues through Waiv, the recent spin-out of Owkin’s diagnostic division, as Owkin refocuses on its core mission of developing biological artificial superintelligence.
KEY QUOTE:
“At Owkin, we believe the future of the pharmaceutical industry is agentic. Our experience, multimodal data, and agentic infrastructure allows us to build various complex agents supporting our pharmaceutical partners, including competitive intelligence agents to support quick decisions by executives.”
Thomas Clozel, CEO and Co-Founder, Owkin
